Dr. Holtan is a transplant and cellular therapy physician-scientist whose research focuses on improving outcomes, with particular expertise in graft-versus-host disease (GVHD) prevention and management, CAR-T and novel cellular therapies, and clinical trial design. Her work has had a direct and measurable impact on global transplant practice — most notably as co-lead of the BMT CTN 1703 trial, published in the New England Journal of Medicine (2023), which established a new standard of care for GVHD prophylaxis. Her translational research program includes the development of amphiregulin as a biomarker for GVHD and the advancement of Pregnyl (hCG) for treatment of high-risk acute GVHD, which received FDA Orphan Drug Designation, as well as leadership of the Phase 1 VIC-1911 and CD83 for AML CAR T clinical trials. Beyond the bench and bedside, her academic interests extend to transplant program operations, high reliability systems design, FACT accreditation standards, and the organizational structures that shape how cellular therapy is delivered. Outside of medicine, she previously held a national record in powerlifting, an experience that informs her perspective on resilience, discipline, and the physiology of human performance.